Showing 5271-5280 of 10567 results for "".
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction. During a presentation at the 2026 Music City SCALE meeting in Nashville, Terrence
- Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Losshttps://practicaldermatology.com/news/seen-study-suggests-hair-care-regimen-may-enhance-minoxidil-response-in-women-with-hair-loss/2487130/SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with
- From SCALE 2026: Microneedling Treatment Reduces Periorbital Wrinkle Severityhttps://practicaldermatology.com/news/microneedling-treatment-reduces-periorbital-wrinkle-severity/2487121/A prospective clinical study presented at the 2026 Music City SCALE Annual Meeting demonstrated significant improvement in periorbital wrinkles following treatment with the SkinStylus SteriLock MicroSystem (Hydrafacial LLC). The study evaluated the safety and effic
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Pharmacal Recalls MG217 Eczema Cream Lot Over Staph Contaminationhttps://practicaldermatology.com/news/pharmacal-recalls-mg217-eczema-cream-lot-over-staph-contamination/2487116/Pharmacal has issued a nationwide consumer-level recall of 1 lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, 6-oz tube, after the product was found to be contaminated with Staphylococcus aureus, according to a company announcement pos
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://practicaldermatology.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual